Age‐Related Differences in Management of Heart Disease: A Study of Cardiac Medication Use in an Older Cohort

BACKGROUND: Previous studies have suggested suboptimal use of cardiac medications for secondary prevention after myocardial infarction (MI) and atrial fibrillation (AF), especially among older people.

[1]  G. MacGregor,et al.  Survey of use of anticoagulation in patients with atrial fibrillation. , 1993, BMJ.

[2]  L. Goldman,et al.  Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. , 1998, Pacing and clinical electrophysiology : PACE.

[3]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[4]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[5]  E F Cook,et al.  Comparative Reproducibility and Validity of Systems for Assessing Cardiovascular Functional Class: Advantages of a New Specific Activity Scale , 1981, Circulation.

[6]  L K Gottlieb,et al.  Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice? , 1994 .

[7]  D. Singer,et al.  National patterns of warfarin use in atrial fibrillation. , 1996, Archives of internal medicine.

[8]  J. O'connell,et al.  Atrial fibrillation and stroke prevention in the community. , 1996, Age and ageing.

[9]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[10]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[11]  H. Krumholz,et al.  Aspirin for Secondary Prevention after Acute Myocardial Infarction in the Elderly: Prescribed Use and Outcomes , 1996, Annals of Internal Medicine.

[12]  E. Antman,et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.

[13]  K. Teo,et al.  Changes in acute myocardial infarction risk and patterns of practice for patients older and younger than 70 years, 1987-90. , 1992, The Canadian journal of cardiology.

[14]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.

[15]  H. Krumholz,et al.  Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. , 1995, Circulation.

[16]  G. Lamas,et al.  Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. , 1992, The New England journal of medicine.

[17]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[18]  J. Alpert,et al.  Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. , 1992, The American journal of medicine.

[19]  J. Whittle,et al.  Is warfarin underused in the treatment of elderly persons with atrial fibrillation? , 1997, Archives of internal medicine.

[20]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[21]  Z. J. Lipowski.  Letter: Psychosomatic medicine. , 1974, Lancet.

[22]  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.

[23]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[24]  H. Krumholz,et al.  Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age. , 1997, The American journal of cardiology.

[25]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  L Goldman,et al.  Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction , 1997 .

[28]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[29]  E. Antman,et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.

[30]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[31]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[32]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.